Search results for " progress."

showing 10 items of 1281 documents

The relationship between transient elastography and histological collagen proportionate area for assessing fibrosis in chronic viral hepatitis

2012

Collagen proportionate area (CPA) has a better correlation with hepatic venous pressure gradient (HVPG) than with Ishak stage. Liver stiffness measurement (LSM) is proposed as non invasive marker of portal hypertension/disease progression. Our aim was to compare LSM and CPA with Ishak staging in chronic viral hepatitis, and HVPG in HCV hepatitis after transplantation. One hundred and sixty-nine consecutive patients with chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infections pre/post liver transplantation (LT), had a liver biopsy combined with LSM (transient elastography), CPA (biopsies stained with Sirius Red and evaluated by digital image analysis and expressed as CPA) and H…

AdultLiver CirrhosisMalemedicine.medical_specialtyCirrhosisHepatitis C virusmedicine.medical_treatmentBiopsyLiver transplantationmedicine.disease_causeGastroenterologyYoung AdultHepatitis B ChronicInternal medicinemedicineImage Processing Computer-AssistedHumansheterocyclic compoundsAgedtransient elastography histological collagen proportionate area fibrosis chronic viral hepatitis.medicine.diagnostic_testbusiness.industryfibrosisGastroenterologyHepatologyHepatitis C ChronicMiddle Agedmedicine.diseasetransient elastographychronic viral hepatitisLiver TransplantationTransplantationhistological collagen proportionate areaLiver biopsyMultivariate Analysiscardiovascular systemDisease ProgressionElasticity Imaging TechniquesRegression AnalysisFemaleCollagenTransient elastographyViral hepatitisbusiness
researchProduct

Long-term follow-up of hepatitis C virus-positive patients with persistently normal serum transaminases

2013

Material and methods. This study prospectively evaluated the progression of liver disease in a group of anti-HCV-positive patients with persistently normal ALT levels (PNALT) who were HCV-RNA positive. Patients selected for this study were those who presented with PNALT according to the Italian Association for the Study of the Liver (AISF) criteria in the year 1995/96 and underwent liver biopsy. They were divided into two groups according to their ALT evolution. Forty-five patients were included in this study. Results. After a median follow-up time of 180 months twenty-five of them maintained PNALT, but two of these developed liver cirrhosis (LC) in a mean time of 174 and 202 months, respec…

AdultLiver CirrhosisMalemedicine.medical_specialtyCirrhosisLong term follow upSpecialties of internal medicineNormal serumChronic hepatitis CGastroenterologyAntiviral AgentsBody Mass IndexLiver diseaseInterferon treatmentInternal medicinemedicineHumansLongitudinal StudiesProspective StudiesUltrasonography Doppler ColorChronic hepatitis C. Persistently normal transaminases. Liver histology. Progression of disease. Interferon treatment.Proportional Hazards ModelsHepatologymedicine.diagnostic_testbusiness.industrySignificant differenceHistologyAlanine TransaminaseGeneral MedicineHepatitis C AntibodiesHepatitis C ChronicMiddle Agedmedicine.diseaseSurgeryHepatitis C Virus PositiveLiverRC581-951Liver biopsyDisease ProgressionElasticity Imaging TechniquesRNA ViralFemaleBiopsy Large-Core NeedlePersistently normal transaminasesbusinessLiver histologyProgression of disease
researchProduct

Focal confluent fibrosis in cirrhotic liver: natural history studied with serial CT.

2009

The objective of this study was to assess the long-term natural history of focal confluent fibrosis in cirrhotic liver with CT.Two radiologists retrospectively reviewed in consensus 118 liver CT examinations in 26 patients (19 men, seven women; age range, 32-68 years; mean age, 50 years) performed over approximately 6 years. Helical CT scans were obtained before and 30-35 and 65-70 seconds after injection of 125-150 mL of contrast medium at a rate of 4-5 mL/s. Proof of cirrhosis was based on liver transplantation (n = 6), biopsy (n = 9), or imaging findings (n = 11). The number, location, and attenuation of fibrotic lesions and presence of trapped vessels were evaluated. Variation of hepati…

AdultLiver CirrhosisMalemedicine.medical_specialtyCirrhotic liverCirrhosismedicine.medical_treatmentContrast MediaIothalamate MeglumineLiver transplantationFibrosisTriiodobenzoic AcidsBiopsymedicineHumansRadiology Nuclear Medicine and imagingAgedRetrospective Studiesmedicine.diagnostic_testbusiness.industryGeneral MedicineMiddle Agedmedicine.diseaseHelical ctNatural historyContrast mediumDisease ProgressionLinear ModelsRadiographic Image Interpretation Computer-AssistedFemaleRadiologybusinessTomography Spiral ComputedAJR. American journal of roentgenology
researchProduct

Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the ev…

2013

Biopsy is still the gold standard for the diagnosis of nonalcoholic steatohepatitis but the definition may vary among pathologists, a drawback especially in evaluation of biopsies for clinical trials. We previously developed a scoring system (steatosis, activity, fibrosis [SAF]) allowing the use of an algorithm (fatty liver inhibition of progression [FLIP]) for the classification of liver injury in morbid obesity. The aim of this study was to determine whether the use of the SAF score and FLIP algorithm can decrease interobserver variations among pathologists. In a first session, pathologists categorized 40 liver biopsies of patients with nonalcoholic fatty liver disease (NAFLD) according t…

AdultLiver CirrhosisMalemedicine.medical_specialtyConcordanceBiopsySettore MED/08 - Anatomia PatologicaSeverity of Illness IndexFibrosisNon-alcoholic Fatty Liver DiseaseInternal medicineSAF steatosis activity fibrosis.Nonalcoholic fatty liver diseaseBiopsyNAS nonalcoholic steatohepatitis activity scoremedicineHumansAgedObserver VariationHepatologymedicine.diagnostic_testbusiness.industryFatty liverGold standard (test)HepatologyMiddle Agedmedicine.diseaseFatty LiverLiverNASH nonalcoholic steatohepatitiDisease ProgressionFemaleNAFLD nonalcoholic fatty liver diseaseSteatosisbusinessAlgorithmAlgorithmsHepatology (Baltimore, Md.)
researchProduct

Evaluating the association of serum ferritin and hepatic iron with disease severity in non‐alcoholic fatty liver disease

2019

Background & Aims Hyperferritinemia, with or without increased hepatic iron, represents a common finding in non‐alcoholic fatty liver disease (NAFLD). However, it is unclear whether it reflects hepatic inflammation or true iron‐overload and, in case the latter is confirmed, whether this influences disease progression. We therefore explored the association between serum ferritin, degree and pattern of hepatic iron deposition and liver disease severity in patients with NAFLD. Methods We selected 468 patients with biopsy‐proven NAFLD from 2 European centres. Iron, hepatic and metabolic parameters were collected at the time of liver biopsy. Iron deposits in hepatocytes and reticuloendothelial c…

AdultLiver CirrhosisMalemedicine.medical_specialtyIron OverloadBiopsyGastroenterologyhistology03 medical and health sciencesLiver diseaseiron0302 clinical medicineFibrosisInternal medicinemedicineHumansRetrospective StudiesMetabolic SyndromeHepatologymedicine.diagnostic_testbiologybusiness.industryferritinFatty livernon-alcoholic fatty liver diseaseMononuclear phagocyte systemMiddle Agedmedicine.diseaseFerritinLogistic ModelsLiver030220 oncology & carcinogenesisLiver biopsyFerritinsDisease Progressionbiology.proteinFemale030211 gastroenterology & hepatologyAlcoholic fatty liverferritin; histology; iron; non-alcoholic fatty liver diseaseSteatohepatitisbusinessLiver International
researchProduct

Predicting Mortality Risk in Patients With Compensated HCV-Induced Cirrhosis: A Long-Term Prospective Study

2009

OBJECTIVES: The identification of prognostic factors associated with mortality is crucial in any clinical setting. METHODS: We enrolled in a prospective study 352 patients with compensated hepatitis C virus (HCV)-induced cirrhosis, consecutively observed between 1989 and 1992. At entry, patients underwent upper endoscopy to detect esophageal varices, and were then surveilled by serial clinical and ultrasonographic examination. The model for end-stage liver disease (MELD) score was calculated with information collected at enrollment. Baseline predictors and intercurrent events associated with mortality were assessed using the Cox regression model. RESULTS: During a median follow-up of 14.4 y…

AdultLiver CirrhosisMalemedicine.medical_specialtyTime FactorsCirrhosisBiopsy Fine-NeedleKaplan-Meier EstimateEsophageal and Gastric VaricesAntiviral AgentsRisk AssessmentSeverity of Illness IndexGastroenterologyCohort StudiesPredictive Value of TestsCause of DeathInternal medicineEpidemiologyConfidence IntervalsmedicineHumansProspective StudiesRisk factorProspective cohort studyAgedProbabilityProportional Hazards ModelsCause of deathSettore MED/12 - GastroenterologiaHepatologybusiness.industryGastroenterologyInterferon-alphavirus diseasesHepatitis CHepatitis C ChronicMiddle Agedmedicine.diseaseImmunohistochemistrySurvival Analysisliver cirrhosis natural historyDisease ProgressionFemalebusinessRisk assessmentLiver FailureFollow-Up StudiesCohort studyThe American Journal of Gastroenterology
researchProduct

Hepatitis C virus-specific T-cell-derived transforming growth factor beta is associated with slow hepatic fibrogenesis.

2011

Up to 4 million persons in the USA have chronic hepatitis C (CHC) (1). Despite a decline in overall HCV infections, the number of patients with end stage liver disease due to CHC will increase for the next 2 decades (2). Even with highly effective novel therapies, currently 30–50% of infected individuals fail treatment (3). Therefore, a better understanding of mechanisms involved in CHC-related liver disease progression could permit more efficient therapies. Adaptive effector T cells (frequently assessed by measuring production of prototypic T helper 1 cytokine IFNγ) play an important role in control of HCV infection during the acute phase (4). In CHC, effector HCV-specific T cell immune re…

AdultLiver CirrhosisMalemedicine.medical_treatmentT cellGene ExpressionHepacivirusBiologyCD8-Positive T-LymphocytesT-Lymphocytes RegulatoryCollagen Type IArticleInterferon-gammaImmune systemTransforming Growth Factor betamedicineHepatic Stellate CellsCytotoxic T cellHumansIL-2 receptorAgedHepatologyViral Core ProteinsFOXP3Hepatitis C ChronicMiddle AgedInterleukin-10Collagen Type I alpha 1 ChainInterleukin 10Cytokinemedicine.anatomical_structureCross-Sectional StudiesLiverImmunologyDisease ProgressionFemaleMatrix Metalloproteinase 1CD8Hepatology (Baltimore, Md.)
researchProduct

Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic aden…

2020

Abstract Background Chemotherapy is effective in metastatic pancreatic adenocarcinoma (mPA), but new approaches are still needed to improve patients' survival and quality of life. We have previously published good efficacy and tolerability results on a sequential treatment strategy of gemcitabine followed by an intensified FOLFIRI (5FU+irinotecan) regimen. In the present study, we evaluated the same sequence but replaced gemcitabine by the new gemcitabine + nab-paclitaxel standard first-line combination. Patients and methods We randomised chemotherapy-naive patients with proven mPA, bilirubin levels ≤1.5 upper limit of normal values and performance status 0–2 to alternately receive gemcitab…

AdultMale0301 basic medicineCancer Researchmedicine.medical_specialtyPaclitaxelPopulationLeucovorinPhases of clinical researchAdenocarcinomaNeutropeniaIrinotecanDeoxycytidineGastroenterology03 medical and health sciences0302 clinical medicineAlbuminsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansNeoplasm MetastasiseducationAgededucation.field_of_studyDrug Substitutionbusiness.industryMiddle Agedmedicine.diseaseGemcitabineNeoadjuvant TherapyProgression-Free SurvivalGemcitabinePancreatic NeoplasmsIrinotecanTreatment Outcome030104 developmental biologyOncologyTolerability030220 oncology & carcinogenesisDisease ProgressionFOLFIRICamptothecinFemaleFluorouracilFrancebusinessFebrile neutropeniamedicine.drugEuropean Journal of Cancer
researchProduct

Association of CYP2R1 rs10766197 with MS risk and disease progression

2017

Background MS is a neurodegenerative autoimmune disease resulting from a complex interaction of genetic and environmental factors. Among these, vitamin D and genetic variants associated with vitamin D-metabolism gain great attention. The aim of our study was to assess five SNPs in NADSYN1 and CYP2R1 genes in relation to serum 25-OH-vitamin D3 levels in MS patients and controls. Methods 25-OH-vitamin D3 levels and genotyping of CYP2R1- and NADSYN1-SNPs were investigated both in MS patients and in healthy controls. Results The analysis revealed lower 25-OH-vitamin D3 concentrations in MS patients than in controls and an association of rs10766197 CYP2R1 SNP with MS risk. After stratifying MS p…

AdultMale0301 basic medicineOncologymedicine.medical_specialtyPathologyMultiple SclerosisGenotypeSingle-nucleotide polymorphismPolymorphism Single NucleotideSeverity of Illness IndexpolymorphismDisability Evaluation03 medical and health sciencesCellular and Molecular NeuroscienceSex Factors0302 clinical medicineInternal medicinegendermedicineVitamin D and neurologyHumansSNPGenetic Predisposition to DiseaseNADSYN1AlleleCytochrome P450 Family 2GenotypingRetrospective Studiesbusiness.industryMultiple sclerosisCase-control studyvitamin dMiddle Agedmedicine.diseaseMinor allele frequency030104 developmental biologyCase-Control Studiesmultiple sclerosiDisease ProgressionCYP2R1Cholestanetriol 26-MonooxygenaseFemaleCarbon-Nitrogen Ligases with Glutamine as Amide-N-Donorgeneticbusiness030217 neurology & neurosurgeryJournal of Neuroscience Research
researchProduct

Observational Prospective Natural History of Patients with Sanfilippo Syndrome Type B

2017

To evaluate the natural course of disease progression in patients with Sanfilippo syndrome type B (mucopolysaccharidosis type IIIB), identify potential end points for future therapy trials, and characterize biomarkers related to the disease.A prospective, multicenter study was conducted. Baseline, 6-month, and 12-month assessments included neurodevelopmental status (Bayley Scales of Infant Development, Third edition), adaptive status (Vineland Adaptive Behavior Scales, Second Edition), volumetric brain magnetic resonance imaging, cerebrospinal fluid heparan sulfate, and urine glycosaminoglycan (GAG) measurements.Nineteen patients aged 1.6-31.7 years were enrolled. Over 12 months, cognition,…

AdultMale0301 basic medicinePediatricsmedicine.medical_specialtyAdolescentDiseaseBayley Scales of Infant DevelopmentMucopolysaccharidosis IIIYoung Adult03 medical and health sciences0302 clinical medicineMucopolysaccharidosis IIImedicineHumansLongitudinal StudiesProspective StudiesYoung adultChildProspective cohort studyCerebrospinal FluidGlycosaminoglycansSanfilippo syndromemedicine.diagnostic_testbusiness.industryBrainInfantMagnetic resonance imagingmedicine.diseaseMagnetic Resonance ImagingVineland Adaptive Behavior Scale030104 developmental biologyNeurodevelopmental DisordersChild PreschoolPediatrics Perinatology and Child HealthDisease ProgressionFemaleHeparitin SulfatebusinessBiomarkers030217 neurology & neurosurgeryThe Journal of Pediatrics
researchProduct